🇪🇺 Cabazitaxel (XRP6258) in European Union

EMA authorised Cabazitaxel (XRP6258) on 17 March 2011

Marketing authorisation

EMA — authorised 17 March 2011

  • Application: EMEA/H/C/002018
  • Marketing authorisation holder: Sanofi Winthrop Industrie
  • Local brand name: Jevtana
  • Indication: Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
  • Status: approved

Read official source →

Other Oncology approved in European Union

Frequently asked questions

Is Cabazitaxel (XRP6258) approved in European Union?

Yes. EMA authorised it on 17 March 2011.

Who is the marketing authorisation holder for Cabazitaxel (XRP6258) in European Union?

Sanofi Winthrop Industrie holds the EU marketing authorisation.